ArticleCase reports in ophthalmological medicine2026
Netarsudil-Induced Honeycomb Keratopathy in an Eye With Iridocorneal Endothelial Syndrome.
Article in Case reports in ophthalmological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To describe a case of netarsudil-associated honeycomb keratopathy in a patient with iridocorneal endothelial (ICE) syndrome. Observations: A 43-year-old male with a history of Cogan-Reese variant ICE syndrome presented with ocular irritation, foreign body sensation, blurred vision, photosensitivity, and discharge in the right eye 2 weeks after initiating topical netarsudil 0.02% for secondary angle-closure glaucoma. Slit lamp exam and anterior segment optical coherence tomography demonstrated diffuse reticular epithelial cysts, consistent with netarsudil-induced honeycomb keratopathy. Three weeks after netarsudil cessation, slit lamp exam showed complete resolution of corneal edema. Conclusions and Importance: Endothelial cell dysfunction in ICE syndrome may be a risk factor for patients to develop reversible netarsudil-induced honeycomb keratopathy. Ophthalmologists should exercise caution when prescribing netarsudil for glaucoma management in patients with pre-existing corneal pathologies, including those with ICE syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.